DE20202562U1 - Micronutrient combination product with probiotics and prebiotics - Google Patents
Micronutrient combination product with probiotics and prebioticsInfo
- Publication number
- DE20202562U1 DE20202562U1 DE20202562U DE20202562U DE20202562U1 DE 20202562 U1 DE20202562 U1 DE 20202562U1 DE 20202562 U DE20202562 U DE 20202562U DE 20202562 U DE20202562 U DE 20202562U DE 20202562 U1 DE20202562 U1 DE 20202562U1
- Authority
- DE
- Germany
- Prior art keywords
- vitamin
- combination product
- lactobacillus
- product containing
- micronutrient combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000018291 probiotics Nutrition 0.000 title claims description 94
- 239000006041 probiotic Substances 0.000 title claims description 93
- 239000011785 micronutrient Substances 0.000 title claims description 62
- 235000013369 micronutrients Nutrition 0.000 title claims description 62
- 239000013066 combination product Substances 0.000 title claims description 53
- 229940127555 combination product Drugs 0.000 title claims description 53
- 235000013406 prebiotics Nutrition 0.000 title claims description 19
- 239000000047 product Substances 0.000 claims description 43
- 230000000529 probiotic effect Effects 0.000 claims description 40
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 26
- 229940088594 vitamin Drugs 0.000 claims description 25
- 229930003231 vitamin Natural products 0.000 claims description 25
- 235000013343 vitamin Nutrition 0.000 claims description 25
- 239000011782 vitamin Substances 0.000 claims description 25
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 24
- 241000194031 Enterococcus faecium Species 0.000 claims description 20
- 229920001202 Inulin Polymers 0.000 claims description 20
- 229940029339 inulin Drugs 0.000 claims description 20
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 20
- 239000011573 trace mineral Substances 0.000 claims description 19
- 235000013619 trace mineral Nutrition 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 16
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 16
- 239000004310 lactic acid Substances 0.000 claims description 16
- 235000014655 lactic acid Nutrition 0.000 claims description 16
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 235000019154 vitamin C Nutrition 0.000 claims description 14
- 239000011718 vitamin C Substances 0.000 claims description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 13
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 13
- 229930003268 Vitamin C Natural products 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 13
- 239000011701 zinc Substances 0.000 claims description 13
- 229910052725 zinc Inorganic materials 0.000 claims description 13
- 235000016804 zinc Nutrition 0.000 claims description 13
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 12
- 229910052742 iron Inorganic materials 0.000 claims description 12
- 239000011669 selenium Substances 0.000 claims description 12
- 229910052711 selenium Inorganic materials 0.000 claims description 12
- 235000011649 selenium Nutrition 0.000 claims description 12
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 11
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 11
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 11
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 11
- 244000199866 Lactobacillus casei Species 0.000 claims description 11
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 11
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 11
- 244000057717 Streptococcus lactis Species 0.000 claims description 11
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 11
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 11
- 229910052804 chromium Inorganic materials 0.000 claims description 11
- 239000011651 chromium Substances 0.000 claims description 11
- 229910052802 copper Inorganic materials 0.000 claims description 11
- 239000010949 copper Substances 0.000 claims description 11
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 11
- 229940017800 lactobacillus casei Drugs 0.000 claims description 11
- 229910052750 molybdenum Inorganic materials 0.000 claims description 11
- 239000011733 molybdenum Substances 0.000 claims description 11
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 10
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 10
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 10
- 229940093797 bioflavonoids Drugs 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 8
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- 235000021466 carotenoid Nutrition 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 229960003512 nicotinic acid Drugs 0.000 claims description 8
- 235000001968 nicotinic acid Nutrition 0.000 claims description 8
- 239000011664 nicotinic acid Substances 0.000 claims description 8
- 229940055726 pantothenic acid Drugs 0.000 claims description 8
- 239000011713 pantothenic acid Substances 0.000 claims description 8
- 235000019161 pantothenic acid Nutrition 0.000 claims description 8
- 235000019155 vitamin A Nutrition 0.000 claims description 8
- 239000011719 vitamin A Substances 0.000 claims description 8
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 229940045997 vitamin a Drugs 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 7
- 239000011630 iodine Substances 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 6
- 150000001747 carotenoids Chemical class 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims description 5
- 239000011772 phylloquinone Substances 0.000 claims description 5
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- -1 iodine, carotenoids Chemical class 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 3
- 244000215068 Acacia senegal Species 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- 239000002535 acidifier Substances 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 239000007968 orange flavor Substances 0.000 claims description 3
- 229940085605 saccharin sodium Drugs 0.000 claims description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 2
- 241000193755 Bacillus cereus Species 0.000 claims description 2
- 229920002498 Beta-glucan Polymers 0.000 claims description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241001608472 Bifidobacterium longum Species 0.000 claims description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 2
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 241000194032 Enterococcus faecalis Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 2
- 241000509544 Lactobacillus gallinarum Species 0.000 claims description 2
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 2
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 241000186428 Propionibacterium freudenreichii Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 2
- 241000204115 Sporolactobacillus inulinus Species 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 2
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003284 iron Drugs 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229940091258 selenium supplement Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims 4
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 4
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 claims 2
- 241000186604 Lactobacillus reuteri Species 0.000 claims 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims 1
- 239000011795 alpha-carotene Substances 0.000 claims 1
- 235000003903 alpha-carotene Nutrition 0.000 claims 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 claims 1
- 235000013734 beta-carotene Nutrition 0.000 claims 1
- 239000011648 beta-carotene Substances 0.000 claims 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims 1
- 229960002747 betacarotene Drugs 0.000 claims 1
- 229940070404 citrus bioflavonoids Drugs 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 229960001031 glucose Drugs 0.000 claims 1
- 229940001882 lactobacillus reuteri Drugs 0.000 claims 1
- 235000012680 lutein Nutrition 0.000 claims 1
- 229960005375 lutein Drugs 0.000 claims 1
- 239000001656 lutein Substances 0.000 claims 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 1
- 235000012661 lycopene Nutrition 0.000 claims 1
- 239000001751 lycopene Substances 0.000 claims 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims 1
- 229960004999 lycopene Drugs 0.000 claims 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 description 19
- 210000000936 intestine Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- 229930003779 Vitamin B12 Natural products 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 235000019163 vitamin B12 Nutrition 0.000 description 6
- 239000011715 vitamin B12 Substances 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 229960002477 riboflavin Drugs 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 229930003471 Vitamin B2 Natural products 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 235000019164 vitamin B2 Nutrition 0.000 description 4
- 239000011716 vitamin B2 Substances 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002475 laxative effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 101150063569 slgA gene Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229940082632 vitamin b12 and folic acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
ORTHOMOL PHARMAZEUTISCHE VERTRIEBS GMBHORTHOMOL PHARMACEUTICAL SALES GMBH
ORTHOMOL PHARMAZEUTISCHE VERTRIEBS GMBHORTHOMOL PHARMACEUTICAL SALES GMBH
Mikronährstoffkombinationsprodukt mit Pro- und PrebiotikaMicronutrient combination product with pro- and prebiotics
Die vorliegende Erfindung betrifft ein Pro- und Prebiotika enthaltendes Mikronährstoffkombinationsprodukt, insbesondere mit Enterococcus faecium, sowie dessen Verwendung als diätetisches Lebensmittel für besondere medizinische Zwecke. Das erfindungsgemäße Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika (Orthomol® Immun Pro) ist zur diätetischen Behandlung bei Störungen der Darmflora und des darmassoziierten Immunsystems, z.B. bei Allergien, nach Chemo- und Strahlentherapie und nach Antibiotikaeinnahme geeignet. Das erfindungsgemäße Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika unterstützt insbesondere die Abwehrkräfte.The present invention relates to a micronutrient combination product containing probiotics and prebiotics, in particular with Enterococcus faecium, and its use as a dietary food for special medical purposes. The micronutrient combination product with probiotics and prebiotics according to the invention (Orthomol® Immun Pro) is suitable for the dietary treatment of disorders of the intestinal flora and the intestinal-associated immune system, e.g. in the case of allergies, after chemotherapy and radiotherapy and after taking antibiotics. The micronutrient combination product with probiotics and prebiotics according to the invention particularly supports the immune system.
SAM:saSAM:sa
Achenbachstrasse 43 ■ 40237 DüsseldorfAchenbachstrasse 43 ■ 40237 Düsseldorf
Tel. +49 (0)211 669 698 40 ■ Fax +49 (0)211 669 698 60 ■ http://www.maiwald.de ■ mail@maiwald.deTel. +49 (0)211 669 698 40 ■ Fax +49 (0)211 669 698 60 ■ http://www.maiwald.de ■ mail@maiwald.de
Geschäftsführer: Dr. WarKfMJiMaId -XSrTiZoltter fcftJrnm,#Di. Stefan IflKhdlSki >KRB Nr,M0413.:Managing Director: Dr. WarKfMJiMaId -XSrTiZoltter fcftJrnm, # Di. Stefan IflKhdlSki >KRB Nr,M0413.:
Es ist allgemein bekannt, dass ein intaktes Immunsystem ein wichtiger Faktor der menschlichen Gesundheit ist und eine funktionierende körpereigene Abwehr den besten Schutz gegenüber Angriffen von Viren, Bakterien und Umweltschadstoffen bietet. Der Zustand des Immunsystems hängt insbesondere von einer ausreichenden nutritiven Zufuhr von Mikronährstoffen ab.It is well known that an intact immune system is an important factor in human health and that a functioning body defense system offers the best protection against attacks from viruses, bacteria and environmental pollutants. The condition of the immune system depends in particular on an adequate nutritional supply of micronutrients.
Die Resorption von Mikronährstoffen aus dem Darm wird durch viele Erkrankungen, Medikamente sowie durch Stress behindert. Insbesondere stressbedingte Ernährungsgewohnheiten können vielfach unbemerkt zu Defiziten in der Vitamin- und Mineralstoffversorgung des Organismus führen und als Folge negative Rückwirkungen auf den allgemeinen Gesundheitszustand zeigen.The absorption of micronutrients from the intestine is hindered by many diseases, medications and stress. In particular, stress-related eating habits can often lead to unnoticed deficiencies in the body's vitamin and mineral supply and, as a result, have negative effects on general health.
Die im Stand der Technik bekannten Vitaminprodukte enthalten verschiedenste Zusammensetzungen von Vitaminen und Spurenelementen, die jedoch nicht auf eine ganzheitliche Stimulation des gesamten Immunsystems ausgerichtet sind. So enthalten ein Großteil dieser Zusammensetzungen hohe Anteile an antioxidativ wirkenden Vitaminen und Spurenelementen, jedoch keine probiotischen Kulturen. Ein Nachteil dieser Produkte ist ihre mangelnde Berücksichtigung des dannassoziierten Immunsystems, das ein wichtiges Organ der körpereigenen Immunabwehr ist.The vitamin products known in the state of the art contain a wide variety of compositions of vitamins and trace elements, but these are not aimed at holistically stimulating the entire immune system. The majority of these compositions contain high levels of antioxidant vitamins and trace elements, but no probiotic cultures. A disadvantage of these products is that they do not take into account the immune system associated with them, which is an important organ of the body's own immune defense.
Die Tagesdosis erhältlicher Produkte zur Unterstützung des Immunsystems wird vielfach in Form einer einzelnen Tablette oder Kapsel verabreicht, um dem Bedürfnis des Verbrauchers nach möglichst einfacher Anwendung entgegen zu kommen, ohne möglichen negativen Interaktionen der Inhaltsstoffe ausreichend Rechnung zu tragen. Ein Nachteil der erhältlichen Produkte besteht darin, dass eine Kombination von probiotischen Kulturen und des Prebiotikums Inulin gegebenenfalls mit von Vitamin C bei gemeinsamer oraler Verabreichung eine stark abführende Wirkung hat.The daily dose of available products to support the immune system is often administered in the form of a single tablet or capsule in order to meet the consumer's need for the easiest possible use without adequately taking into account possible negative interactions between the ingredients. A disadvantage of the available products is that a combination of probiotic cultures and the prebiotic inulin, possibly with vitamin C, has a strong laxative effect when administered orally together.
-3--3-
Ein weiterer Nachteil ist, dass bei vielen Produkten Magensäure zu einer weitreichenden Zersetzung der probiotischen Kulturen, wie Milchsäurebakterien, führt. Die Menge an probiotischen Kulturen, die letztlich den Darm erreicht, ist verschwindend gering. Darüber hinaus wird die Anzahl der lebend den Darm erreichenden probiotischen Kulturen angesichts der am Wirkort herrschenden schlechten Wachstums- bzw. Lebensbedingungen noch weiter reduziert, so dass ein starker Aktivitätsverlust innerhalb kurzer Zeit eintritt.Another disadvantage is that in many products, stomach acid leads to extensive decomposition of the probiotic cultures, such as lactic acid bacteria. The amount of probiotic cultures that ultimately reach the intestine is negligible. In addition, the number of probiotic cultures that reach the intestine alive is reduced even further due to the poor growth and living conditions at the site of action, so that a strong loss of activity occurs within a short period of time.
Es besteht daher ein Bedarf an einem Mikronährstoffkombinationsprodukt, bei dem eine möglichst hohe Anzahl an probiotischen Kulturen den Wirkort lebend erreicht und die gleichzeitig eine wesentlich verlängerte durchschnittliche Lebensdauer aufweisen. Weiterhin besteht ein Bedarf, ein hinsichtlich seiner Zusammensetzung optimal formuliertes bzw. dosiertes Mikronährstoffkombinationsprodukt mit einer verbesserten nutritiven Immunstimulierung zur Verfügung zu stellen. Zudem besteht Bedarf an einem Mittel, das eine abführende Wirkung zuverlässig vermeidet.There is therefore a need for a micronutrient combination product in which the highest possible number of probiotic cultures reach the site of action alive and which at the same time have a significantly longer average lifespan. There is also a need to provide a micronutrient combination product with an optimally formulated and dosed composition and improved nutritional immune stimulation. There is also a need for a product that reliably avoids a laxative effect.
Es ist daher die Aufgabe der vorliegenden Erfindung, ein Mikronährstoffkombinationsprodukt zur Verfügung zu stellen, dass die vorgenannten Nachteile des Standes der Technik überwindet. Insbesondere ist es die Aufgabe der vorliegenden Erfindung, ein Mittel zur Verfügung zu stellen, dass eine umfassende nutritive Stimulierung des Immunsystems bietet.It is therefore the object of the present invention to provide a micronutrient combination product that overcomes the aforementioned disadvantages of the prior art. In particular, it is the object of the present invention to provide an agent that offers comprehensive nutritional stimulation of the immune system.
Diese Aufgabe wird durch ein hinsichtlich seiner Bestandteile optimiert formuliertes Probiotika enthaltendes Mikronährstoffkombinationsprodukt gelöst, das mindestens zwei Produktanteile mit unterschiedlicher Zusammensetzung umfasst, wobei ein erster Anteil als wirksame Bestandteile Probiotika umfasst und ein zweiter Anteil als wirksame Bestandteile Prebiotika bzw. Präbiotika, Spurenelemente, Vitamine und sekundäre Pflanzenstoffe umfasst.This object is achieved by a micronutrient combination product containing probiotics which is optimally formulated with regard to its components and which comprises at least two product components with different compositions, wherein a first component comprises probiotics as active components and a second component comprises prebiotics or prebiotics, trace elements, vitamins and secondary plant substances as active components.
Besonders bevorzugt wird diese Aufgabe durch ein hinsichtlich seiner Bestandteile optimiert formuliertes Probiotika enthaltendes Mikronährstoffkombinationsprodukt gelöst, dasThis task is particularly preferably solved by a micronutrient combination product containing probiotics that is optimally formulated with regard to its components and that
mindestens zwei Produktanteile mit unterschiedlicher Zusammensetzung umfasst, wobei ein erstes Produkt als wirksame Bestandteile ausschließlich Probiotika umfasst und das zweite Produkt frei von Probiotika ist und als wirksame Bestandteile Prebiotika, Spurenelemente, Vitamine und sekundäre Pflanzenstoffe umfasst.comprises at least two product parts with different compositions, wherein a first product comprises exclusively probiotics as active ingredients and the second product is free of probiotics and comprises prebiotics, trace elements, vitamins and secondary plant substances as active ingredients.
Die probiotischen Kulturen des Probiotika enthaltenden Mikronährstoffkombinationsproduktes sind ausgewählt aus der Gruppe umfassend Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuten, Lactobacillus rhamnosus, Lactobacillus salivarius, Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium longum, Enterococcus faecalis, Enterococcus faecium, Lactococcus lactis, Leuc. mesenteroides, Ped. acidilactici, Sporolactobacillus inulinus, Strep, thermophilus, Bacillus cereus, Escherichia coli, Propionibacterium freudenreichii und/oder Saccharomyces cerevisiae, vorzugsweise Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius und/oder Enterococcus faecium.The probiotic cultures of the micronutrient combination product containing probiotics are selected from the group comprising Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuten, Lactobacillus rhamnosus acillus salivarius, Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium longum, Enterococcus faecalis, Enterococcus faecium, Lactococcus lactis, Leuc. mesenteroides, Ped. acidilactici, Sporolactobacillus inulinus, Strep, thermophilus, Bacillus cereus, Escherichia coli, Propionibacterium freudenreichii and/or Saccharomyces cerevisiae, preferably Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius and/or Enterococcus faecium.
Ein besonderer Vorteil ist, dass durch die erfindungsgemäße Verwendung von probiotischen Kulturen, umfassend Milchsäurebakterien, wie Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius und/oder Enterococcus faecium, in Folge gebildeter Milchsäure der pH-Wert im Darmtrakt gesenkt wird, wodurch Spurenelemente, insbesondere Eisen und Zink, besser in Lösung gehen und hierdurch in erhöhtem Maße resorbiert werden können. Darüber hinaus können die probiotischen Kulturen die resorbierende Oberfläche des Darms vergrößern und somit weiterhin zu einer Erhöhung der Resorption beitragen.A particular advantage is that the use of probiotic cultures according to the invention, comprising lactic acid bacteria such as Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius and/or Enterococcus faecium, lowers the pH value in the intestinal tract as a result of the lactic acid formed, which means that trace elements, in particular iron and zinc, dissolve better and can therefore be absorbed to a greater extent. In addition, the probiotic cultures can increase the absorbing surface of the intestine and thus further contribute to increasing absorption.
Besonders bevorzugt ist bei dem erfindungsgemäßen Probiotika enthaltenden Mikronährstoffkombinationsprodukt die Kombination Enterococcus faecium und Milchsäurebakterien.Particularly preferred in the micronutrient combination product containing probiotics according to the invention is the combination of Enterococcus faecium and lactic acid bacteria.
Es hat sich überraschend gezeigt, dass insbesondere das erfindungsgemäß verwendete probiotische Bakterium Enterococcus faecium einen deutlich verbessernden Einfluss auf die Wirksamkeit der Milchsäurebakterien zeigt. Enterococcus faecium kann den pH-Wert des Darmes schon im vorderen Bereich des Darmes ausgehend vom Magen senken. Bedingt durch diese Vorsäuerung wird die Wachstumsrate bzw. -geschwindigkeit der probiotischen Kulturen, insbesondere der Milchsäurebakterien, deutlich gesteigert, so dass der pH-Wert im Darm weiter sinkt, was zu einer zusätzlichen Erhöhung der Vermehrungsrate der probiotischen Kulturen im Darrri führt.It has surprisingly been shown that the probiotic bacterium Enterococcus faecium used according to the invention has a significantly improving effect on the effectiveness of the lactic acid bacteria. Enterococcus faecium can lower the pH value of the intestine in the front area of the intestine starting from the stomach. Due to this pre-acidification, the growth rate or speed of the probiotic cultures, especially the lactic acid bacteria, is significantly increased, so that the pH value in the intestine continues to fall, which leads to an additional increase in the reproduction rate of the probiotic cultures in the intestine.
Ein weiterer vorteilhafter Effekt des erfindungsgemäßen Mikronährstoffkombinationsproduktes ist, dass die erhöhte Anzahl lebender Milchsäurebakterien im Darm das Eindringen von Viren, pathogenen Bakterien und Toxinen vermindert. Überraschend hat sich gezeigt, dass die Verwendung des erfindungsgemäßen Gemischs der probiotischen Bakterienstämme als ergänzende Ernährung, insbesondere umfassend mit der Verwendung des Stammes Enterococcus faecium, eine deutliche Steigerung der Produktion spezifischer Antikörper, wie slgA und natürlicher Killerzellen bewirkt.A further advantageous effect of the micronutrient combination product according to the invention is that the increased number of living lactic acid bacteria in the intestine reduces the penetration of viruses, pathogenic bacteria and toxins. Surprisingly, it has been shown that the use of the mixture of probiotic bacterial strains according to the invention as a supplementary diet, in particular comprising the use of the strain Enterococcus faecium, causes a significant increase in the production of specific antibodies such as slgA and natural killer cells.
Das Probiotika enthaltende Mikronährstoffkombinationsprodukt umfasst erfindungsgemäß Prebiotika ausgewählt aus der Gruppe umfassend Inulin, Fructooligosaccharide und ß-Glucan.According to the invention, the micronutrient combination product containing probiotics comprises prebiotics selected from the group comprising inulin, fructooligosaccharides and ß-glucan.
Es hat sich überraschend gezeigt, dass das erfindungsgemäße Mikronährstoffkombinationsprodukt durch die Zugabe des Prebiotikums Inulin zum Überleben der probiotischen Kulturen im Darm beiträgt.It has surprisingly been shown that the micronutrient combination product according to the invention contributes to the survival of the probiotic cultures in the intestine through the addition of the prebiotic inulin.
&bgr;■■« * · * ·&bgr;■■« * · * ·
-6--6-
Die Vitamine, die das Probiotika enthaltende Mikronährstoffkombinationsprodukt umfasst, sind erfindungsgemäß ausgewählt aus der Gruppe umfassend Vitamin A, Vitamin C, natürliches Vitamin E, Vitamin Bi, Vitamin B2, Niacin, Vitamin B^, Vitamin Bn, Vitamin Ki, Vitamin D3, Folsäure, Panthothensäure und/oder Biotin.
Die sekundären Pflanzenstoffe des Probiotika enthaltenden Mikronährstoffkombinationsprodukt sind erfindungsgemäß ausgewählt aus der Gruppe umfassend Carotinoide und BioflavonoideAccording to the invention, the vitamins comprising the micronutrient combination product containing probiotics are selected from the group comprising vitamin A, vitamin C, natural vitamin E, vitamin Bi, vitamin B2, niacin, vitamin B^, vitamin Bn, vitamin Ki, vitamin D3, folic acid, pantothenic acid and/or biotin.
The secondary plant substances of the micronutrient combination product containing probiotics are selected according to the invention from the group comprising carotenoids and bioflavonoids
Vorteilhaft ist weiterhin die optimierte Zusammensetzung bezüglich des Gehalts an Vitamin C, Inulin und probiotischen Kulturen, wodurch eine abführende Wirkung auf Grund zu hoher Vitamin C-Gehalte bei gleichzeitiger Anwesenheit von Inulin und probiotischen Kulturen vermieden wird. Zudem ist eine Kombination von Vitamin C und Bioflavonoiden von Vorteil, wodurch die ernährungsühysiologische Aktivität des Vitamin C und dessen Funktion vorteilhaft ergänzt werden kann.Another advantage is the optimized composition with regard to the content of vitamin C, inulin and probiotic cultures, which avoids a laxative effect due to excessive vitamin C content in the presence of inulin and probiotic cultures. A combination of vitamin C and bioflavonoids is also advantageous, whereby the nutritional-physiological activity of vitamin C and its function can be advantageously supplemented.
Die Spurenelemente, die das Probiotika enthaltende Mikronährstoffkombinationsprodukt umfasst, sind ausgewählt aus der Gruppe umfassend Calcium, Selen, Eisen, Zink, Mangan, Kupfer, Chrom, Molybdän, Iod, Phosphor, Magnesium, Kalium und/oder Chlorid, vorzugsweise Selen, Eisen, Zink, Mangan, Kupfer, Chrom, Molybdän und/oder Iod.The trace elements comprising the micronutrient combination product containing probiotics are selected from the group comprising calcium, selenium, iron, zinc, manganese, copper, chromium, molybdenum, iodine, phosphorus, magnesium, potassium and/or chloride, preferably selenium, iron, zinc, manganese, copper, chromium, molybdenum and/or iodine.
Es hat sich gezeigt, dass durch den optimierten Gehalt an Spurenelementen, wie Selen, Eisen, Zink, Mangan, Kupfer, Chrom, Molybdän und/oder Iod eine deutlich bessere Stimulierung des Immunsystems unter Einbeziehung des Darm-assoziierten Immunsystems und dadurch eine Erhöhung der Abwehrkräfte eintritt. Dies ist zur diätetischen Behandlung bei Störungen der Darmflora und des darmassoziierten Immunsystems wichtig, z.B. bei Allergien, nach Chemo- und Strahlentherapie, nach Antibiotikaeinnahme.It has been shown that the optimized content of trace elements such as selenium, iron, zinc, manganese, copper, chromium, molybdenum and/or iodine leads to a significantly better stimulation of the immune system, including the gut-associated immune system, and thus an increase in the body's defenses. This is important for the dietary treatment of disorders of the intestinal flora and the gut-associated immune system, e.g. in the case of allergies, after chemotherapy and radiotherapy, after taking antibiotics.
Ein weiterer Vorteil des erfindungsgemäßen Mikronährstoffkombinationsproduktes besteht in der synergistischen Wirkung im Hinblick auf eine umfassende ganzheitliche Stimulierung des körpereigenen Immunsystems. Das Immunsystem wird durch die optimierte Kombination der Vitamine und Spurenelemente, insbesondere der Vitamine C und E, Selen und Zink, gestärkt. Darüber hinaus wird der Darm, der einen wichtigen Teil des menschlichen Immunsystems darstellt, miteinbezogen. Die verlängerte Lebensdauer der probiotischen Kulturen und des damit bedingten niedrigen pH-Wertes führen im Dünndarm zu einer verbesserten Resorption der Spurenelemente sowie darüber hinaus zu einer erhöhten eigenen Synthese von Vitaminen, z. B. Thiamin, Riboflavin Vitamin B12 und Folsäure, die der Mensch zusätzlich resorbiert.Another advantage of the micronutrient combination product according to the invention is the synergistic effect with regard to a comprehensive, holistic stimulation of the body's own immune system. The immune system is strengthened by the optimized combination of vitamins and trace elements, in particular vitamins C and E, selenium and zinc. In addition, the intestine, which is an important part of the human immune system, is also included. The extended lifespan of the probiotic cultures and the resulting low pH value lead to improved absorption of trace elements in the small intestine and also to increased synthesis of vitamins, e.g. thiamine, riboflavin, vitamin B12 and folic acid, which humans also absorb.
Die Produkte des Probiotika enthaltenden Mikronährstoffkombinationsprodukts können fest-, flüssig und/oder gelförmig vorliegen.The products of the micronutrient combination product containing probiotics can be in solid, liquid and/or gel form.
In einer bevorzugten Ausführungsform liegen die Inhaltsstoffe des Probiotika enthaltenden Mikronährstoffkombinationsproduktes in Form wenigstens zwei getrennt vorliegender Produkte, vorzugsweise in Form wenigstens drei getrennt vorliegender Produkte und besonders bevorzugt in Form wenigstens vier getrennt vorliegender Produkte vor.In a preferred embodiment, the ingredients of the micronutrient combination product containing probiotics are in the form of at least two separate products, preferably in the form of at least three separate products and particularly preferably in the form of at least four separate products.
Erfindungsgemäß umfasst das Probiotika enthaltende Mikronährstoffkombinationsprodukt wenigstens ein getrennt vorliegendes erstes Produkt umfassend als wirksame Bestandteile probiotische Kulturen, vorzugsweise Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius; und wenigstens ein zweites getrennt vorliegendes Produkt umfassend als wirksame Bestandteile Vitamin A, Vitamin C, Vitamin E, Vitamin Bi, Vitamin B2, Niacin, Vitamin Be, Vitamin B12, Vitamin Ki, Vitamin D3, Folsäure, Pantothensäure, Biotin, Selen, Eisen, Zink, Mangan, Kupfer, Chrom, Molybdän, Iod, Carotinoide, Bioflavonoide, Inulin.According to the invention, the micronutrient combination product containing probiotics comprises at least one separately present first product comprising as active ingredients probiotic cultures, preferably Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius; and at least one second separately present product comprising as active ingredients vitamin A, vitamin C, vitamin E, vitamin Bi, vitamin B2, niacin, vitamin Be, vitamin B12, vitamin Ki, vitamin D3, folic acid, pantothenic acid, biotin, selenium, iron, zinc, manganese, copper, chromium, molybdenum, iodine, carotenoids, bioflavonoids, inulin.
Ein weiterer vorteilhafter Effekt des Probiotika enthaltenden Mikronährstoffproduktes ergibt sich aus der Möglichkeit einer separaten Verabreichung der getrennt vorliegenden Produkte. Es ist bekannt, dass ein großer Teil der aufgenommenen probiotischen Bakterien die Passage durch den Magen-Darmtrakt nicht überleben und geringe Mengen lebender Milchsäurebakterien nicht ausreichen, den pH-Wert des Darms wirksam abzusenken. Erfindungsgemäß kann das Probiotika enthaltende Mikronährstoffkombinationsprodukt ein erstes Granulat umfassen, welches ausschließlich die probiotischen Kulturen umfasst, und ein zweites Granulat, das frei von Probiotika ist und die Vitamine, Spurenelemente, sekundäre Pfianzenstoffe und Inulin umfasst. Beispielsweise kann das die probiotischen Kulturen enthaltende Granulat vorzugsweise getrennt von den Mahlzeiten und dem zweiten Granulat verabreicht werden, so dass die Kulturen den Darm unter geringerer Schädigung durch zersetzende Säuren erreichen können. Diese Milchsäurebakterien können bereits im Dünndarm ihre Aktivität entfalten und durch ihre Milchsäureproduktion den pH-Wert im Dünn- und Dickdarm erniedrigen, so dass zu einem späteren Zeitpunkt die Resorption der den Darm erreichenden Spurenelemente durch die Aktivität der Milchsäurebakterien gesteigert wird.A further advantageous effect of the micronutrient product containing probiotics results from the possibility of separate administration of the separately present products. It is known that a large proportion of the ingested probiotic bacteria do not survive the passage through the gastrointestinal tract and small amounts of live lactic acid bacteria are not sufficient to effectively lower the pH value of the intestine. According to the invention, the micronutrient combination product containing probiotics can comprise a first granulate which exclusively comprises the probiotic cultures and a second granulate which is free of probiotics and comprises the vitamins, trace elements, secondary plant substances and inulin. For example, the granulate containing the probiotic cultures can preferably be administered separately from the meals and the second granulate so that the cultures can reach the intestine with less damage from decomposing acids. These lactic acid bacteria can already develop their activity in the small intestine and lower the pH value in the small and large intestine through their lactic acid production, so that at a later point in time the absorption of the trace elements reaching the intestine is increased by the activity of the lactic acid bacteria.
Vorteilhaft ist weiterhin, dass sich eine hohe Zahl lebender Milchsäurebakterien im Darmtrakt ansiedeln kann, die durch die erfindungsgemäße Menge des Prebiotikums Inulin eine deutliche Erhöhung ihrer Lebensdauer zeigen. Diese Erhöhung der Lebensdauer verlängert die für eine effektive Resorption zur Verfügung stehende Zeitspanne. Dies ist insbesondere von großem Vorteil, da die Resorption der Vitalstoffe ihrerseits einige Zeit benötigt. Durch diese vorteilhaften Eigenschaften führt die Verwendung des erfindungsgemäßen Mittels auch zu einem verbesserten Blutplasmaspiegel der Mikronährstoffe.Another advantage is that a large number of living lactic acid bacteria can settle in the intestinal tract, and their lifespan is significantly increased by the amount of the prebiotic inulin according to the invention. This increase in lifespan extends the time available for effective absorption. This is particularly advantageous because the absorption of the vital substances takes some time. Due to these advantageous properties, the use of the agent according to the invention also leads to an improved blood plasma level of the micronutrients.
Vorzugsweise liegt das Probiotika enthaltende Mikronährstoffkombinationsprodukt umfassend wenigstens zwei Produkte mit unterschiedlicher Zusammensetzung in Form von bis 10 Tabletten, vorzugsweise 1 bis 5 Tabletten, 0 bis 10 Kapseln, vorzugsweise 1 bis 5Preferably, the micronutrient combination product containing probiotics comprises at least two products with different compositions in the form of up to 10 tablets, preferably 1 to 5 tablets, 0 to 10 capsules, preferably 1 to 5
Kapseln, O bis 5 Lösungen, vorzugsweise 1 bis 2 Lösungen und/oder 0 bis 5 Granulate, vorzugsweise 1 bis 3 Granulate, vor.Capsules, 0 to 5 solutions, preferably 1 to 2 solutions and/or 0 to 5 granules, preferably 1 to 3 granules.
Es hat sich gezeigt, dass Granulate insbesondere für den Darm die verträglichste Darreichungsform darstellen. Vorteilhaft ist darüber hinaus, dass diese Granulatform eine erhöhte Löslichkeit der Komponenten gewährleistet. Eine Einnahme in Form von Tabletten oder auch Filmtabletten kann dazu führen, dass die Inhaltsstoffe in Magen und Darm zeitlich unterschiedlich freigesetzt werden, was zu einer verzögerten und verschlechterten Resorption führen kann.It has been shown that granules are the most well-tolerated form of administration, particularly for the intestines. Another advantage is that this form of granules ensures increased solubility of the components. Taking the drug in the form of tablets or film-coated tablets can lead to the ingredients being released at different times in the stomach and intestines, which can lead to delayed and impaired absorption.
Das Probiotika enthaltende Mikronährstoffkombinationsprodukt kann Zusätze umfassen, die die Bioverfügbarkeit, Löslichkeit und/oder Lösegeschwindigkeit verbessern und/oder Zusätze, ausgewählt aus der Gruppe umfassend Sprengmittel, Stoffe die die Haltbarkeit verbessern, geschmacksmaskierende und/oder geschmacksverbessernde Stoffe, Stoffe zur Erhöhung oder Senkung der Viskosität, aufweisen.The micronutrient combination product containing probiotics may comprise additives that improve the bioavailability, solubility and/or dissolution rate and/or additives selected from the group comprising disintegrants, substances that improve shelf life, taste-masking and/or taste-enhancing substances, substances for increasing or reducing viscosity.
Das Probiotika enthaltende Mikronährstoffkombinationsprodukt kann Zusätze umfassen, die ausgewählt aus der Gruppe umfassend Dextrose, Maltodextrin, Maisstärke, natürliches Orangenaroma, Sauerungsmittel Zitronensäure, Gummi Arabicum, Fructooligosaccharide, Saccharin-Natrium und/oder Enzyme sein können.The micronutrient combination product containing probiotics may comprise additives selected from the group comprising dextrose, maltodextrin, corn starch, natural orange flavor, acidifier citric acid, gum arabic, fructooligosaccharides, saccharin sodium and/or enzymes.
Das erste getrennt vorliegende Produkt des Probiotika enthaltenden Mikronährstoffkombinationsproduktes kann, bezogen auf eine Tagesdosis, als wirksame Bestandteile ausschließlich 2 &khgr; 109 KBE probiotische Kulturen umfassen und das zweite getrennt vorliegende Produkt frei von probiotischen Kulturen sein und, bezogen auf eine Tagesdosis, 0,3-0,5 g Vitamine, 9-11 mg Spurenelemente, 2 g Prebiotika und 20-30 mg sekundärer Pflanzenstoffe umfassen.The first separate product of the micronutrient combination product containing probiotics can comprise, based on a daily dose, exclusively 2 x 10 9 CFU of probiotic cultures as active ingredients and the second separate product can be free of probiotic cultures and comprise, based on a daily dose, 0.3-0.5 g of vitamins, 9-11 mg of trace elements, 2 g of prebiotics and 20-30 mg of secondary plant substances.
J SJ S
-10--10-
Die vostehenden Mengenangaben sind lediglich beispielhaft, da das Mikronährstoffkombinationsprodukt auch Zusätze, Begleitstoffe und/oder Rohstoffe enthalten kann, die viel schwerer sind als der bzw. die eigentlichen Wirkstoffe, so dass die angegebenen Mengen bezogen auf eine Tagesdosis natürlich wesentlich niedriger oder auch höher sein können.The quantities given above are merely examples, as the micronutrient combination product may also contain additives, accompanying substances and/or raw materials that are much heavier than the actual active ingredient(s), so that the quantities given in relation to a daily dose may of course be considerably lower or higher.
Die Probiotika können auch Fructooligosaccharide zur frühzeitigen Unterstützung der Kulturen enthalten.The probiotics may also contain fructooligosaccharides to provide early support to the cultures.
Es hat sich gezeigt, dass das erfindungsgemäße Mittel eine verbesserte Wirkung bezüglich einer ausgewogenen Versorgung mit Vitaminen und Spurenelementen kombiniert mit optimiertem Nutzen und Verträglichkeit der probiotischen Kulturen aufweist. Durch die Eigenschaften und Merkmale der Vitamine, probiotischen Kulturen und des Prebiotikums Inulin weist die erfindungsgemäße Zusammensetzungen gegenüber üblichen Zusammensetzungen eine verbesserte ernährungsphysiologische Wirkung im Hinblick auf Störungen der Darmflora und des darmassoziierten Immunsystems auf.It has been shown that the agent according to the invention has an improved effect with regard to a balanced supply of vitamins and trace elements combined with optimized benefits and tolerability of the probiotic cultures. Due to the properties and characteristics of the vitamins, probiotic cultures and the prebiotic inulin, the composition according to the invention has an improved nutritional-physiological effect compared to conventional compositions with regard to disorders of the intestinal flora and the intestinal-associated immune system.
Das erfindungsgemäße Probiotika enthaltenende Mikronährstoffproduktes ist insbesondere verwendbar zur diätetischen Behandlung bei Störungen, Beschwerden oder Krankheiten, ausgewählt aus der Gruppe umfassend:The micronutrient product containing probiotics according to the invention is particularly suitable for the dietary treatment of disorders, complaints or diseases selected from the group comprising:
Allergien wie atopisches Ekzem, allergisches Asthma, Rhitinitis allergica, Nahrungsmittelallergie;Allergies such as atopic eczema, allergic asthma, allergic rhitinitis, food allergy;
nach Chemo- und Strahlentherapie;after chemotherapy and radiotherapy;
nach Antibiotikaeinnahme;after taking antibiotics;
Gastroenteritiden;gastroenteritis;
Laktoseintoleranz;Lactose intolerance;
chronisch-entzündliche Darmerkrankungen wie Colitis ulceros, Morbus Crohn;chronic inflammatory bowel diseases such as ulcerative colitis, Crohn’s disease;
hepatische Enzephalopathie; und/oder
- Hypercholesterinämie.hepatic encephalopathy; and/or
- Hypercholesterolemia.
• · ♦*• · ♦*
Es hat sich gezeigt, dass bei Verabreichung des erfindungsgemäßen Mikronährstoffproduktes allein oder in Kombination mit Arzneimitteln, Störungen, Beschwerden oder Krankheiten, wie oben angegeben, spürbar verringert und/oder schneller gelindert werden, oder gar nicht erst auftreten, im Vergleich zu üblichen im Stand der Technik bekannten Mikronährstoffkombinationsprodukten. Ohne auf eine bestimmte Theorie festgelegt zu sein, wird vermutet, dass die Kombination Enterococcus faecium und Milchsäurebakterien einen hierfür verantwortlich sein könnte, da Enterococcus faecium einen deutlich verbessernden Einfluss auf die Wirksamkeit der Milchsäurebakterien zeigt. Wie bereits beschrieben kann Enterococcus faecium den pH-Wert des Darmes schon im vorderen Bereich des Darmes ausgehend vom Magen senken. Bedingt durch diese Vorsäuerung wird die Wachstumsrate bzw. -geschwindigkeit der probiotischen Kulturen, insbesondere der Milchsäurebakterien, deutlich gesteigert, so dass der pH-Wert im Darm weiter sinkt.It has been shown that when the micronutrient product according to the invention is administered alone or in combination with drugs, disorders, complaints or illnesses as stated above are noticeably reduced and/or alleviated more quickly, or do not occur at all, compared to conventional micronutrient combination products known in the prior art. Without being tied to a specific theory, it is suspected that the combination of Enterococcus faecium and lactic acid bacteria could be responsible for this, since Enterococcus faecium has a significantly improving effect on the effectiveness of the lactic acid bacteria. As already described, Enterococcus faecium can lower the pH value of the intestine in the front area of the intestine starting from the stomach. Due to this pre-acidification, the growth rate or speed of the probiotic cultures, in particular the lactic acid bacteria, is significantly increased, so that the pH value in the intestine continues to fall.
Der erste getrennt vorliegende Produktanteil des Probiotika enthaltenden Mikronährstoffkombinationsproduktes kann als wirksame Bestandteile, bezogen auf eine Tagesdosis:The first separate product portion of the micronutrient combination product containing probiotics can contain as active ingredients, based on a daily dose:
a. 5 &khgr; 108- 5 &khgr; 109 KBE, bevorzugt 1-3 &khgr; 109 KBE, probiotische Kulturen ausgewählt aus der Gruppe umfassend Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius;a. 5 x 10 8 - 5 x 10 9 CFU, preferably 1-3 x 10 9 CFU, probiotic cultures selected from the group comprising Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius;
umfassen und der zweite getrennt vorliegende Produktanteil kann, bezogen auf eine Tagesdosis, als wirksame Bestandteile die Stoffe umfassen:and the second separate product portion may comprise, based on a daily dose, the following active ingredients:
a. 1000-4000 IE, bevorzugt 2000-3000 IE, Vitamin A;a. 1000-4000 IU, preferably 2000-3000 IU, vitamin A;
b. 100-500 mg, bevorzugt 200-400 mg, Vitamin C;b. 100-500 mg, preferably 200-400 mg, vitamin C;
c. 10-80 mg, bevorzugt 25-45 mg, natürliches Vitamin E;c. 10-80 mg, preferably 25-45 mg, natural vitamin E;
d. 1-6 mg, bevorzugt 2-4 mg, Vitamin Bi;d. 1-6 mg, preferably 2-4 mg, vitamin B12;
e. 1 -7 mg, bevorzugt 3-4 mg, Vitamin B2;e. 1-7 mg, preferably 3-4 mg, vitamin B2;
f. 10-80 mg, bevorzugt 25-45 mg, Niacin;f. 10-80 mg, preferably 25-45 mg, niacin;
g. 1-7 mg, bevorzugt 3-4 mg Vitamin Bö; h. 1-10 /ig, bevorzugt 3-7 /ig, Vitamin B12;g. 1-7 mg, preferably 3-4 mg vitamin B12; h. 1-10 mg, preferably 3-7 mg, vitamin B12;
i. 10-100 /Ag, bevorzugt 30-70 /Ag, Vitamin K1;i. 10-100 /Ag, preferably 30-70 /Ag, vitamin K 1 ;
j. 1-10 /Ag, bevorzugt 4-6 &mgr;g, Vitamin D3;j. 1-10 /Ag, preferably 4-6 μg, vitamin D3;
k. 200-1000 /Ag, bevorzugt 400-800 /Ag, Folsäure;k. 200-1000 /Ag, preferably 400-800 /Ag, folic acid;
1. 5-50 mg, bevorzugt 10-25 mg, Panthothensäure;1. 5-50 mg, preferably 10-25 mg, pantothenic acid;
m. 50-300 /Ag, bevorzugt 150-225 /Ag, Biotin;m. 50-300 /Ag, preferably 150-225 /Ag, biotin;
n. 5-80 /Ag, bevorzugt 20-50 &mgr;&xgr;, Selen;n. 5-80 /Ag, preferably 20-50 μξ, selenium;
o. 0,5-10 mg, bevorzugt 1-4 mg, Eisen;o. 0.5-10 mg, preferably 1-4 mg, iron;
p. 3-15 mg, bevorzugt 5-10 mg, Zink;p. 3-15 mg, preferably 5-10 mg, zinc;
q. 0.3-3 mg, bevorzugt 0,5-2 mg, Mangan;q. 0.3-3 mg, preferably 0.5-2 mg, manganese;
r. 0,2-3 mg, bevorzugt 0,4-2 mg, Kupfer;r. 0.2-3 mg, preferably 0.4-2 mg, copper;
s. 10-100 /xg, bevorzugt 20-50 /Ag, Chrom;s. 10-100 /xg, preferably 20-50 /Ag, chromium;
t. 10-100 /Ag, bevorzugt 30-60 /tg, Molybdän;t. 10-100 /Ag, preferably 30-60 /tg, molybdenum;
u. 50-200 &mgr;g, bevorzugt 100-150 /ig, Iod;and 50-200 μg, preferably 100-150 μg, iodine;
v. 1-15 mg, bevorzugt 3-7 mg, Carotinoide;v. 1-15 mg, preferably 3-7 mg, carotenoids;
w. 5-50 mg, bevorzugt 15-30 mg, Bioflavonoide;w. 5-50 mg, preferably 15-30 mg, bioflavonoids;
x. 1-6 g, bevorzugt 2-4 g, Inulin.x. 1-6 g, preferably 2-4 g, inulin.
Der Gegenstand der vorliegenden Erfindung wird anhand des nachfolgenden Beispiels näher erläutert.The subject matter of the present invention is explained in more detail using the following example.
-13--13-
Probiotika enthaltendes Mikronährstoffkombinationsprodukt umfassend zwei Granulate I und II unterschiedlicher Zusammensetzung:Micronutrient combination product containing probiotics comprising two granules I and II of different composition:
Granulat I:Granules I:
&khgr; 109 KBE probiotische Kulturen, umfassend Bifidobacterium lactis bzw. animalis, Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius;× 10 9 CFU probiotic cultures comprising Bifidobacterium lactis or animalis, Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius;
Als Hilfsstoffe werden Maisstärke, Maltodextrin, Fructooligosaccharide, und/oder Enzyme zugesetzt.Corn starch, maltodextrin, fructooligosaccharides and/or enzymes are added as excipients.
Granulat II:Granules II:
2500 IE Vitamin A 300 mg Vitamin C; 36 mg natürliches Vitamin E; 3 mg Vitamin Bi; 3,6 mg Vitamin B2; 35 mg Niacin; 3,6 mg Vitamin Bö;2500 IU vitamin A; 300 mg vitamin C; 36 mg natural vitamin E; 3 mg vitamin Bi; 3.6 mg vitamin B2; 35 mg niacin; 3.6 mg vitamin B12;
6 ^g Vitamin B12; 60 &mgr;g Vitamin Ki; 5 ßg Vitamin D3; 800 &mgr;g Folsäure; 18 mg Panthothensäure; 180/ig Biotin; 30 ßg Selen; 2 mg Eisen;6 ^g vitamin B12; 60 µg vitamin Ki; 5 ßg vitamin D 3 ; 800 µg folic acid; 18 mg pantothenic acid; 180% biotin; 30 ßg selenium; 2 mg iron;
7 mg Zink;7 mg zinc;
• ♦ · ·•♦ · ·
-14--14-
500 /xg Mangan;500 /xg manganese;
- 500 &mgr;g Kupfer;
30 &mgr;g Chrom;
50 jug Molybdän;- 500 μg copper;
30 μg chromium;
50 ug molybdenum;
- 100/Xg Iod;- 100/Xg iodine;
5 mg Carotinoide;
20 mg Bioflavonoide;
2 g Inulin.5 mg carotenoids;
20 mg bioflavonoids;
2 g inulin.
Als Hilfsstoffe werden Dextrose, Maltodextrin, Maisstärke, natürliches Orangenaroma, Säuerungsmittel Zitronensäure, und/oder Gummi Arabicum und Saccharin-Natrium zugesetzt.Dextrose, maltodextrin, corn starch, natural orange flavour, acidifier citric acid, and/or gum arabic and saccharin sodium are added as excipients.
Die Gewichtsangaben, wenn nicht anders angegeben, beziehen sich auf eine Tagesdosis.The weight information, unless otherwise stated, refers to a daily dose.
Zweites Produkt: Vitamine + Inulin + Spurenelemente(C) First product: Probiotic cultures
Second product: Vitamins + Inulin + Trace elements
(A) - (B): Vergleichspräparate des Standes der Technik:(A) - (B): State of the art comparative preparations:
(A) Probiotik pur erhältlich bei Dr. Sandner, Münster(A) Pure probiotics available from Dr. Sandner, Münster
(B) BION 3 erhältlich bei Merck, Darmstadt
(C): erfmdungsgemäßes Mikronährstoffpräparat:(B) BION 3 available from Merck, Darmstadt
(C): Micronutrient preparation according to the invention:
entspricht dem erfindungsgemäßen Beispiel 1; Orthomol ® Immun Pro, erhältlich bei der Firma Orthomol GmbH in Langenfeld.corresponds to example 1 according to the invention; Orthomol ® Immun Pro, available from Orthomol GmbH in Langenfeld.
Vs V s
Tabelle I zeigt einen Vergleich des Effektes üblicher Mikronährstoffprodukte verschiedener Zusammensetzungen auf das Immunsystem. Der Tabelle I ist zu entnehmen, dass eine deutliche Stimulierung des Immunsystems durch die kombinierte Gabe probiotischer Kulturen und des Prebiotikums Inulin insbesondere probiotischer Kulturen, Inulin und Spurenelementen erreicht wurde. Es zeigt sich, dass eine Versorgung, die neben den probiotischen Kulturen und Vitaminen insbesondere eine erfindungsgemäße Kombination von probiotischen Kulturen, Vitaminen, Spurenelementen und Inulin aufweist, eine verbesserte Wirkung im Hinblick auf die Stärkung des gesamten körpereigenen Immunsystems auf.Table I shows a comparison of the effect of common micronutrient products with different compositions on the immune system. Table I shows that a significant stimulation of the immune system was achieved through the combined administration of probiotic cultures and the prebiotic inulin, in particular probiotic cultures, inulin and trace elements. It can be seen that a supply which, in addition to the probiotic cultures and vitamins, in particular has an inventive combination of probiotic cultures, vitamins, trace elements and inulin, has an improved effect in terms of strengthening the entire body's immune system.
Claims (16)
das zweite getrennt vorliegende Produkt, bezogen auf eine Tagesdosis, als wirksame Bestandteile die Stoffe umfasst:
the second separate product, based on a daily dose, contains as active ingredients the substances:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20202562U DE20202562U1 (en) | 2002-02-19 | 2002-02-19 | Micronutrient combination product with probiotics and prebiotics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20202562U DE20202562U1 (en) | 2002-02-19 | 2002-02-19 | Micronutrient combination product with probiotics and prebiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE20202562U1 true DE20202562U1 (en) | 2002-05-23 |
Family
ID=7967982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE20202562U Expired - Lifetime DE20202562U1 (en) | 2002-02-19 | 2002-02-19 | Micronutrient combination product with probiotics and prebiotics |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE20202562U1 (en) |
Cited By (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004002501A1 (en) * | 2002-06-26 | 2004-01-08 | Calpis Co., Ltd. | Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy |
| WO2004017979A2 (en) * | 2002-08-16 | 2004-03-04 | Finzelberg Gmbh & Co. Kg | Medicament, food supplement, and fodder additive |
| WO2004032645A1 (en) * | 2002-10-11 | 2004-04-22 | Erber Aktiengesellschaft | Food additive and/or drinking water additive for domestic animals |
| FR2851889A1 (en) * | 2003-03-06 | 2004-09-10 | Larena Sa | Product for restoration of tolerance to antigens useful for dietary or food compositions for prevention of intolerance to alimentary antigens and nonpathogenic bacteria and disturbance of the integrity of the intestinal barrier |
| WO2004112508A1 (en) * | 2003-06-23 | 2004-12-29 | Nestec S.A. | Infant or follow-on formula |
| WO2004112507A1 (en) * | 2003-06-23 | 2004-12-29 | Nestec S.A. | Infant or follow-on formula |
| EP1492549A1 (en) * | 2002-03-13 | 2005-01-05 | Kibow Biotech, Inc. | Compositions and methods for augmenting kidney function |
| EP1602377A1 (en) * | 2003-03-07 | 2005-12-07 | Aureo Co., Ltd. | Composition containing beta-glucan and constipation-relieving drug, immunopotentiator and skin moistening agent using the composition |
| EP1607096A2 (en) * | 2004-06-18 | 2005-12-21 | Dietetics Pharma S.r.l. | Nutraceutical composition containing milk enzymes useful as synbiotic |
| WO2006012536A2 (en) * | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
| AT413334B (en) * | 2002-12-23 | 2006-02-15 | Belihart Josephine | Medically usable solid dosage form comprises freeze-dried live lactic acid bacteria and an excipient powder mixture of inulin and lactose in the form of a directly compressed tablet |
| WO2005109175A3 (en) * | 2004-05-05 | 2006-04-20 | Lifescape Biosciences Inc | Vitamin compositions and treatment methods for metabolic diseases and nutrient deficiencies |
| WO2006027745A3 (en) * | 2004-09-09 | 2006-05-11 | Warburton Technology Ltd | Trace elements |
| WO2006054135A1 (en) * | 2004-11-16 | 2006-05-26 | Anidral S.R.L. | Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality |
| EP1666050A1 (en) * | 2003-08-26 | 2006-06-07 | Obschestvo S Ogranichennoi Otvetstvennostyu Alef- Farma | Use of enrerococcus faecium strains for curing hepatic insufficiency and for regenerating and intensifying metabolism in a liver |
| WO2006133472A1 (en) * | 2005-06-14 | 2006-12-21 | Erber Aktiengesellschaft | Probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive and use thereof |
| WO2008071930A1 (en) | 2006-12-11 | 2008-06-19 | Danisco A/S | Composition |
| EP1964570A1 (en) * | 2007-03-02 | 2008-09-03 | Bufe, Albrecht, Prof. Dr. med. | Pharmaceutical compound to protect against allergies and inflammatory illnesses |
| EP2030642A1 (en) * | 2006-05-26 | 2009-03-04 | José Antonio Cruz Serrano | Gelatinous protein foodstuff and process for its preparation |
| WO2009071578A1 (en) * | 2007-12-03 | 2009-06-11 | Probiotical S.P.A. | Composition based on probiotic bacteria in association with a prebiotic and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of intestinal functionality |
| FR2933848A1 (en) * | 2008-07-18 | 2010-01-22 | Roquette Freres | COMPOSITION OF SOLUBLE INDIGESTIBLE FIBERS AND EUKARYOTIC ORGANISMS HAVING POLYSACCHARIDE WAVES USED IN THE WELL-BEING FIELD |
| US7651680B2 (en) | 2004-06-23 | 2010-01-26 | L'oreal | Methods and compositions for preventing and treating sensitive and dry skin |
| ITMI20090065A1 (en) * | 2009-01-22 | 2010-07-23 | Dietetics Pharma S R L | NUTRACEUTICAL COMPOSITION CONTAINING USEFUL LACTICTS AS SYMBIOTIC. |
| EP2248430A3 (en) * | 2005-02-15 | 2011-01-12 | Barry R. Goldin | A food containing a probiotic and an isolated beta-glucan and methods of use thereof |
| US7879363B2 (en) | 1998-07-07 | 2011-02-01 | Ritter Pharmaceuticals, Inc. | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
| ITMI20092327A1 (en) * | 2009-12-29 | 2011-06-30 | Giuliani Spa | PHARMACEUTICAL OR DIETETIC COMPOSITION FOR THE TREATMENT OF ATOPIA |
| EP2401925A1 (en) * | 2010-06-29 | 2012-01-04 | Rosebud AG | Prebiotic product and manufacturing method |
| US8481299B2 (en) | 2009-03-04 | 2013-07-09 | L'oreal | Use of probiotic microorganisms to limit skin irritation |
| US8486668B2 (en) | 2009-02-24 | 2013-07-16 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US8492124B2 (en) | 2009-02-24 | 2013-07-23 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US9049884B2 (en) | 2009-12-04 | 2015-06-09 | Abbott Laboratories | Methods of modulating inflammation in preterm infants using carotenoids |
| WO2015160314A1 (en) * | 2014-04-16 | 2015-10-22 | SCHWARTZ, I. Sandford | Nutraceutical blend for the enhancement of the immune system |
| WO2016035043A1 (en) * | 2014-09-04 | 2016-03-10 | SMITH, Jerome Shelsley | Probiotic composition |
| US9375444B2 (en) | 2008-08-16 | 2016-06-28 | Protectimmun Gmbh | Composition for prevention and treatment of allergic and/or inflammatory diseases |
| EP3275439A1 (en) * | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| EP3318263A1 (en) * | 2016-11-03 | 2018-05-09 | Cell Biotech Co., Ltd. | Antioxidant composition and composition for improvement of skin conditions |
| US10172793B2 (en) | 2003-12-24 | 2019-01-08 | Ferrosan A.S. | Probiotic tablet formulations |
| US10238897B2 (en) | 2007-09-04 | 2019-03-26 | L'oreal | Use of a lysate of bifidobacterium species for treating sensitive skin |
| US11154731B2 (en) | 2007-09-04 | 2021-10-26 | L'oreal | Cosmetic use of Bifidobacterium species lysate for the treatment of dryness |
| WO2022090335A1 (en) * | 2020-10-28 | 2022-05-05 | Dsm Ip Assets B.V. | Direct delivery of vitamins to rebalance gut microbiome after exposure to antibiotics |
-
2002
- 2002-02-19 DE DE20202562U patent/DE20202562U1/en not_active Expired - Lifetime
Cited By (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7879363B2 (en) | 1998-07-07 | 2011-02-01 | Ritter Pharmaceuticals, Inc. | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
| EP1492549A1 (en) * | 2002-03-13 | 2005-01-05 | Kibow Biotech, Inc. | Compositions and methods for augmenting kidney function |
| EP1492549A4 (en) * | 2002-03-13 | 2005-10-26 | Kibow Biotech Inc | Compositions and methods for augmenting kidney function |
| WO2004002501A1 (en) * | 2002-06-26 | 2004-01-08 | Calpis Co., Ltd. | Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy |
| US8003092B2 (en) | 2002-06-26 | 2011-08-23 | Calpis Co., Ltd. | Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy |
| WO2004017979A2 (en) * | 2002-08-16 | 2004-03-04 | Finzelberg Gmbh & Co. Kg | Medicament, food supplement, and fodder additive |
| WO2004017979A3 (en) * | 2002-08-16 | 2004-04-22 | Finzelberg Gmbh & Co Kg | Medicament, food supplement, and fodder additive |
| WO2004032645A1 (en) * | 2002-10-11 | 2004-04-22 | Erber Aktiengesellschaft | Food additive and/or drinking water additive for domestic animals |
| AT413334B (en) * | 2002-12-23 | 2006-02-15 | Belihart Josephine | Medically usable solid dosage form comprises freeze-dried live lactic acid bacteria and an excipient powder mixture of inulin and lactose in the form of a directly compressed tablet |
| FR2851889A1 (en) * | 2003-03-06 | 2004-09-10 | Larena Sa | Product for restoration of tolerance to antigens useful for dietary or food compositions for prevention of intolerance to alimentary antigens and nonpathogenic bacteria and disturbance of the integrity of the intestinal barrier |
| EP1602377A1 (en) * | 2003-03-07 | 2005-12-07 | Aureo Co., Ltd. | Composition containing beta-glucan and constipation-relieving drug, immunopotentiator and skin moistening agent using the composition |
| EP1602377A4 (en) * | 2003-03-07 | 2009-06-24 | Aureo Co Ltd | Composition containing beta-glucan and constipation-relieving drug, immunopotentiator and skin moistening agent using the composition |
| WO2004112507A1 (en) * | 2003-06-23 | 2004-12-29 | Nestec S.A. | Infant or follow-on formula |
| WO2004112508A1 (en) * | 2003-06-23 | 2004-12-29 | Nestec S.A. | Infant or follow-on formula |
| EP1666050A1 (en) * | 2003-08-26 | 2006-06-07 | Obschestvo S Ogranichennoi Otvetstvennostyu Alef- Farma | Use of enrerococcus faecium strains for curing hepatic insufficiency and for regenerating and intensifying metabolism in a liver |
| EP1666050A4 (en) * | 2003-08-26 | 2008-01-09 | Obschestvo S Ogranichennoi Otv | Use of enrerococcus faecium strains for curing hepatic insufficiency and for regenerating and intensifying metabolism in a liver |
| US10172793B2 (en) | 2003-12-24 | 2019-01-08 | Ferrosan A.S. | Probiotic tablet formulations |
| WO2005109175A3 (en) * | 2004-05-05 | 2006-04-20 | Lifescape Biosciences Inc | Vitamin compositions and treatment methods for metabolic diseases and nutrient deficiencies |
| EP1607096A2 (en) * | 2004-06-18 | 2005-12-21 | Dietetics Pharma S.r.l. | Nutraceutical composition containing milk enzymes useful as synbiotic |
| EP1607096A3 (en) * | 2004-06-18 | 2006-01-04 | Dietetics Pharma S.r.l. | Nutraceutical composition containing milk enzymes useful as synbiotic |
| US7651680B2 (en) | 2004-06-23 | 2010-01-26 | L'oreal | Methods and compositions for preventing and treating sensitive and dry skin |
| WO2006012536A3 (en) * | 2004-07-22 | 2006-05-26 | Andrew J Ritter | Methods and compositions for treating lactose intolerance |
| US9226933B2 (en) | 2004-07-22 | 2016-01-05 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
| WO2006012536A2 (en) * | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
| US8377482B2 (en) | 2004-09-09 | 2013-02-19 | Warburton Technology Limited | Trace elements |
| WO2006027745A3 (en) * | 2004-09-09 | 2006-05-11 | Warburton Technology Ltd | Trace elements |
| US9233130B2 (en) | 2004-11-16 | 2016-01-12 | Probiotical S.P.A. | Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality |
| WO2006054135A1 (en) * | 2004-11-16 | 2006-05-26 | Anidral S.R.L. | Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality |
| US8404228B2 (en) | 2005-02-15 | 2013-03-26 | Sherwood L. Gorbach | Food containing a probiotic and an isolated β-glucan and methods of use thereof |
| US7981412B2 (en) | 2005-02-15 | 2011-07-19 | Gorbach Sherwood L | Food containing a probiotic and an isolated β-glucan and methods of use thereof |
| EP2248430A3 (en) * | 2005-02-15 | 2011-01-12 | Barry R. Goldin | A food containing a probiotic and an isolated beta-glucan and methods of use thereof |
| CN101262779B (en) * | 2005-06-14 | 2011-04-13 | 爱尔伯股份公司 | Probiotic health or fitness promoting foodstuff, feed, and/or drinking water additive and use thereof |
| AU2006257751B9 (en) * | 2005-06-14 | 2011-04-07 | Erber Aktiengesellschaft | Probiotic health and performance promoting food, feed and/or drinking water additive and its use |
| WO2006133472A1 (en) * | 2005-06-14 | 2006-12-21 | Erber Aktiengesellschaft | Probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive and use thereof |
| US8101170B2 (en) | 2005-06-14 | 2012-01-24 | Erber Aktiengesellschaft | Probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive and use thereof |
| AU2006257751B2 (en) * | 2005-06-14 | 2011-03-31 | Erber Aktiengesellschaft | Probiotic health and performance promoting food, feed and/or drinking water additive and its use |
| EP2030642A4 (en) * | 2006-05-26 | 2010-07-28 | Serrano Jose Antonio Cruz | Gelatinous protein foodstuff and process for its preparation |
| EP2030642A1 (en) * | 2006-05-26 | 2009-03-04 | José Antonio Cruz Serrano | Gelatinous protein foodstuff and process for its preparation |
| WO2008071930A1 (en) | 2006-12-11 | 2008-06-19 | Danisco A/S | Composition |
| EP1964570A1 (en) * | 2007-03-02 | 2008-09-03 | Bufe, Albrecht, Prof. Dr. med. | Pharmaceutical compound to protect against allergies and inflammatory illnesses |
| US9950017B2 (en) | 2007-03-02 | 2018-04-24 | Forschungszentrum Borstel | Pharmaceutical composition for protection from allergies and inflammatory disorders |
| US11154731B2 (en) | 2007-09-04 | 2021-10-26 | L'oreal | Cosmetic use of Bifidobacterium species lysate for the treatment of dryness |
| US10238897B2 (en) | 2007-09-04 | 2019-03-26 | L'oreal | Use of a lysate of bifidobacterium species for treating sensitive skin |
| WO2009071578A1 (en) * | 2007-12-03 | 2009-06-11 | Probiotical S.P.A. | Composition based on probiotic bacteria in association with a prebiotic and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of intestinal functionality |
| US9758644B2 (en) | 2008-07-18 | 2017-09-12 | Roquette Freres | Composition of soluble indigestible fibre and of microalgae used in the well-being field |
| US9725585B2 (en) | 2008-07-18 | 2017-08-08 | Roquette Freres | Composition of soluble indigestible fibers and of eukaryotic organisms with a polysaccharide wall, used in the well-being field |
| FR2933848A1 (en) * | 2008-07-18 | 2010-01-22 | Roquette Freres | COMPOSITION OF SOLUBLE INDIGESTIBLE FIBERS AND EUKARYOTIC ORGANISMS HAVING POLYSACCHARIDE WAVES USED IN THE WELL-BEING FIELD |
| US9375444B2 (en) | 2008-08-16 | 2016-06-28 | Protectimmun Gmbh | Composition for prevention and treatment of allergic and/or inflammatory diseases |
| ITMI20090065A1 (en) * | 2009-01-22 | 2010-07-23 | Dietetics Pharma S R L | NUTRACEUTICAL COMPOSITION CONTAINING USEFUL LACTICTS AS SYMBIOTIC. |
| US9579340B2 (en) | 2009-02-24 | 2017-02-28 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US8486668B2 (en) | 2009-02-24 | 2013-07-16 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US9592248B2 (en) | 2009-02-24 | 2017-03-14 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US8785160B2 (en) | 2009-02-24 | 2014-07-22 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US8492124B2 (en) | 2009-02-24 | 2013-07-23 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US9775860B2 (en) | 2009-02-24 | 2017-10-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US9808481B2 (en) | 2009-02-24 | 2017-11-07 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| US8481299B2 (en) | 2009-03-04 | 2013-07-09 | L'oreal | Use of probiotic microorganisms to limit skin irritation |
| US9049884B2 (en) | 2009-12-04 | 2015-06-09 | Abbott Laboratories | Methods of modulating inflammation in preterm infants using carotenoids |
| ITMI20092327A1 (en) * | 2009-12-29 | 2011-06-30 | Giuliani Spa | PHARMACEUTICAL OR DIETETIC COMPOSITION FOR THE TREATMENT OF ATOPIA |
| WO2012001640A1 (en) * | 2010-06-29 | 2012-01-05 | Rosebud Ag | Prebiotic product and method for producing same |
| EP2401925A1 (en) * | 2010-06-29 | 2012-01-04 | Rosebud AG | Prebiotic product and manufacturing method |
| WO2015160314A1 (en) * | 2014-04-16 | 2015-10-22 | SCHWARTZ, I. Sandford | Nutraceutical blend for the enhancement of the immune system |
| WO2016035043A1 (en) * | 2014-09-04 | 2016-03-10 | SMITH, Jerome Shelsley | Probiotic composition |
| WO2018020010A1 (en) * | 2016-07-29 | 2018-02-01 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| US10117854B2 (en) | 2016-07-29 | 2018-11-06 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| EP3275439A1 (en) * | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| US10328059B2 (en) | 2016-07-29 | 2019-06-25 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| EP3318263A1 (en) * | 2016-11-03 | 2018-05-09 | Cell Biotech Co., Ltd. | Antioxidant composition and composition for improvement of skin conditions |
| WO2022090335A1 (en) * | 2020-10-28 | 2022-05-05 | Dsm Ip Assets B.V. | Direct delivery of vitamins to rebalance gut microbiome after exposure to antibiotics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE20202562U1 (en) | Micronutrient combination product with probiotics and prebiotics | |
| DE10206995B4 (en) | Micronutrient combination product with pro- and prebiotics | |
| DE69936740T2 (en) | Oligosaccharide and probiotics containing preparation | |
| EP2124972B1 (en) | Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems | |
| EP0901371B1 (en) | Alteration of microbial populations in the gastrointestinal tract | |
| DE60032599T2 (en) | BACTERIENSTAMM, PROCESSED PLANT EXTRACTS AND PROBIOTIC PREPARATIONS FOR HUMAN AND AUTHENTIC USE | |
| DE60122570T2 (en) | FOOD COMPOSITION FOR IMMUNE DISEASE | |
| DE60204662T2 (en) | PROBIOTICS COMBINATION | |
| AU2007300461B2 (en) | Probiotic oral dosage forms | |
| DE69422066T2 (en) | Diet prescription for pets | |
| EP0931543A1 (en) | Multilayered tablet comprising probiotic microorganisms such as lactobacilli or bifidobacteria | |
| AU2015259359A1 (en) | Compositions and methods for improving human health and nutrition | |
| DE202016008919U1 (en) | Compositions for use in the prevention or treatment of gastrointestinal infection / inflammation in infants or young children | |
| JP2016529309A (en) | Use of a composition comprising a microorganism for increasing intestinal production of butyric acid, folic acid or niacin and / or for reducing intestinal production of succinic acid | |
| SG191418A1 (en) | A nutritional composition comprising fiber and probiotics for reducing stressrelated intestinal symptoms | |
| DE102005062731A1 (en) | New Lactobacillus strains and their use | |
| DE202010008308U1 (en) | Composition for nutritive supplementation or treatment for urinary tract infections and / or bacterial inflammation of the mucous membranes | |
| DE60000825T2 (en) | PHARMACEUTICAL COMPOSITIONS FOR MEDICAL AND VETERINARY USE FOR IMPROVING THE COLOR OF THE COLON IN DYSPEPTIC SYNDROME AND DIARRHOUES IN THE VETERINARY SECTOR | |
| CN111528479A (en) | Probiotics and prebiotics composition for relieving atopic dermatitis function and application | |
| EP1952703B1 (en) | Product including living probiotic micro organisms | |
| EP2658559A1 (en) | Fiber and probiotics for reducing intestinal symptoms related to stress | |
| EP2228067A1 (en) | Probiotic compound and use of same | |
| JP2002522393A (en) | Method for increasing the solubility of nutrient materials using symbiotic lactic acid producing bacteria | |
| WO2010114864A1 (en) | Probiotic oral dosage forms | |
| EP1549155B1 (en) | Food additive and/or drinking water additive for domestic animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R207 | Utility model specification |
Effective date: 20020627 |
|
| R150 | Utility model maintained after payment of first maintenance fee after three years |
Effective date: 20050308 |
|
| R151 | Utility model maintained after payment of second maintenance fee after six years |
Effective date: 20080417 |
|
| R158 | Lapse of ip right after 8 years |
Effective date: 20100901 |